WO2008096791A1 - アシルグアニジン誘導体 - Google Patents

アシルグアニジン誘導体 Download PDF

Info

Publication number
WO2008096791A1
WO2008096791A1 PCT/JP2008/051962 JP2008051962W WO2008096791A1 WO 2008096791 A1 WO2008096791 A1 WO 2008096791A1 JP 2008051962 W JP2008051962 W JP 2008051962W WO 2008096791 A1 WO2008096791 A1 WO 2008096791A1
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
dementia
modulating activity
receptor modulating
ht5a receptor
Prior art date
Application number
PCT/JP2008/051962
Other languages
English (en)
French (fr)
Inventor
Isao Kinoyama
Satoshi Miyamoto
Hiroaki Hoshii
Takehiro Miyazaki
Mayako Yamazaki
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to CA002677995A priority Critical patent/CA2677995A1/en
Priority to EP08710858A priority patent/EP2119704A4/en
Priority to MX2009008507A priority patent/MX2009008507A/es
Priority to JP2008557144A priority patent/JP5287257B2/ja
Priority to US12/526,250 priority patent/US20100324017A1/en
Publication of WO2008096791A1 publication Critical patent/WO2008096791A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)

Abstract

　本発明の課題は、5-HT5A受容体調節作用に基づく、認知症、統合失調症等の、新規かつ優れた治療または予防薬を提供することにある。ピロール環を中心に含む３環性ヘテロ環とグアニジンがカルボニル基を介して結合した構造に特徴を有する化合物が、強力な5-HT5A受容体調節作用と、これに基づく優れた薬理作用を有することを確認し、認知症、統合失調症、双極性障害、注意欠陥多動性障害、特に、認知症や統合失調症の認知障害といった記憶に関わる機能障害の良好な治療または予防薬となりうることを知見して本発明を完成した。
PCT/JP2008/051962 2007-02-07 2008-02-06 アシルグアニジン誘導体 WO2008096791A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002677995A CA2677995A1 (en) 2007-02-07 2008-02-06 Acylguanidine derivative
EP08710858A EP2119704A4 (en) 2007-02-07 2008-02-06 ACYLGUANIDINE DERIVATIVE
MX2009008507A MX2009008507A (es) 2007-02-07 2008-02-06 Derivado de acilguanidina.
JP2008557144A JP5287257B2 (ja) 2007-02-07 2008-02-06 アシルグアニジン誘導体
US12/526,250 US20100324017A1 (en) 2007-02-07 2008-02-06 Acylguanidine derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007028089 2007-02-07
JP2007-028089 2007-02-07

Publications (1)

Publication Number Publication Date
WO2008096791A1 true WO2008096791A1 (ja) 2008-08-14

Family

ID=39681697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051962 WO2008096791A1 (ja) 2007-02-07 2008-02-06 アシルグアニジン誘導体

Country Status (8)

Country Link
US (1) US20100324017A1 (ja)
EP (1) EP2119704A4 (ja)
JP (1) JP5287257B2 (ja)
KR (1) KR20090114439A (ja)
CN (1) CN101627013A (ja)
CA (1) CA2677995A1 (ja)
MX (1) MX2009008507A (ja)
WO (1) WO2008096791A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022633A1 (ja) 2007-08-10 2009-02-19 Astellas Pharma Inc. 二環式アシルグアニジン誘導体
WO2011016504A1 (ja) 2009-08-06 2011-02-10 アステラス製薬株式会社 含窒素環アシルグアニジン誘導体
US20120039804A1 (en) * 2010-06-04 2012-02-16 Philippe Diaz Novel Tricyclic Modulators of Cannabinoid Receptors
EP2480079A1 (en) * 2009-09-23 2012-08-01 Medivation Technologies, Inc. Pyrido(3,4-b)indoles and methods of use
WO2012105588A1 (ja) * 2011-02-02 2012-08-09 アステラス製薬株式会社 テトラヒドロイソキノリン誘導体
US9260429B2 (en) 2008-03-24 2016-02-16 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
WO2021193708A1 (ja) * 2020-03-25 2021-09-30 Jnc株式会社 化合物、液晶組成物および液晶表示素子
US11655244B2 (en) 2017-04-11 2023-05-23 Gsno Therapeutics, Inc. Carbazole compounds and methods of use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104326937B (zh) * 2014-09-03 2016-08-24 天津市肿瘤研究所 抗肿瘤化合物及其医药用途
CN112375029B (zh) * 2020-11-11 2022-03-18 湖北省生物农药工程研究中心 一种咔唑生物碱衍生物及其制备方法和用途
CN116210361A (zh) * 2021-09-29 2023-06-02 京东方科技集团股份有限公司 量子点配体、量子点-配体体系及量子点材料

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US41696A (en) 1864-02-23 Improvement in railroad-track raisers
US5082871A (en) 1986-12-22 1992-01-21 General Electric Company UV-activation of addition cure silicon coatings
DE19724979A1 (de) 1997-06-13 1998-12-17 Basf Ag 3-substituierte Pyrido [3,4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
WO1999020599A1 (en) 1997-10-21 1999-04-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
WO2000017191A2 (fr) 1998-09-23 2000-03-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
JP2002502419A (ja) * 1997-06-04 2002-01-22 イーライ・リリー・アンド・カンパニー ５−ｈｔ▲下１ｆ▼アゴニストとして有用なカルボキサミド
WO2004096771A1 (en) 2003-04-29 2004-11-11 Glaxo Group Limited Biaryl compounds having activity at the 5ht5a receptor
WO2005079845A1 (ja) 2004-02-20 2005-09-01 Astellas Pharma Inc. 片頭痛予防薬
WO2005080322A1 (ja) 2004-02-20 2005-09-01 Astellas Pharma Inc. フルオレン誘導体
US20060229323A1 (en) 2005-04-11 2006-10-12 Alexander Alanine (3,4-Dihydro-quinazolin-2-yl)-indan-1-yl-amines
WO2007018168A1 (ja) 2005-08-08 2007-02-15 Astellas Pharma Inc. アシルグアニジン誘導体またはその塩

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221884B1 (en) * 1997-06-04 2001-04-24 Eli Lilly And Company Carboxamides useful as 5-HT1F agonists

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US41696A (en) 1864-02-23 Improvement in railroad-track raisers
US5082871A (en) 1986-12-22 1992-01-21 General Electric Company UV-activation of addition cure silicon coatings
JP2002502419A (ja) * 1997-06-04 2002-01-22 イーライ・リリー・アンド・カンパニー ５−ｈｔ▲下１ｆ▼アゴニストとして有用なカルボキサミド
DE19724979A1 (de) 1997-06-13 1998-12-17 Basf Ag 3-substituierte Pyrido [3,4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
WO1999020599A1 (en) 1997-10-21 1999-04-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
WO2000017191A2 (fr) 1998-09-23 2000-03-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
WO2004096771A1 (en) 2003-04-29 2004-11-11 Glaxo Group Limited Biaryl compounds having activity at the 5ht5a receptor
WO2005079845A1 (ja) 2004-02-20 2005-09-01 Astellas Pharma Inc. 片頭痛予防薬
WO2005080322A1 (ja) 2004-02-20 2005-09-01 Astellas Pharma Inc. フルオレン誘導体
US20060229323A1 (en) 2005-04-11 2006-10-12 Alexander Alanine (3,4-Dihydro-quinazolin-2-yl)-indan-1-yl-amines
WO2007018168A1 (ja) 2005-08-08 2007-02-15 Astellas Pharma Inc. アシルグアニジン誘導体またはその塩

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
"Bunshi Sekkei", vol. 7, 1990, HIROKAWA PUBLISHING COMPANY, article "Iyakuhin no Kaihatsu", pages: 163 - 198
"Learning & memory", J. CLIN. PSYCHIATRY, vol. 8, 2001, pages 20 - 25
"Protective Groups in Organic Synthesis (3rd edition, 1999)"
"Yuki Gosei", vol. 300, 1992, MARUZEN
AM J PSYCHIATRY, vol. 160, 2003, pages 1209 - 1222
CHEMISTRY LETTERS, 1989, pages 1405 - 1408
CURR. NEUROL. NEUROSCI. REP., vol. 5, no. 6, 2005, pages 455 - 457
CURR. PSYCHIATRY REP., vol. 2, no. 6, pages 473 - 478
DIABETES CARE, vol. 27, 2004, pages 596
EUR. J. PHARMACOL., vol. 346, 13 January 1998 (1998-01-13)
J PHARMACOL EXP THER, vol. 279, 1996, pages 1157 - 73
J. ABNORM. PSYCHOL., 1997
J. CLIN. PSYCHIATRY, vol. 66, no. 5, 2005, pages 658 - 659
J. PSYCHIATR. RES., vol. 38, 2004, pages 371 - 376
J. PSYCHOPHARMACOL., vol. 14, no. 4, 2000, pages 406 - 408
JIKKEN KAGAKU KOZA, vol. 20
JONGEN-RELO A. L. ET AL., 36TH ANNUAL MEETING, SOCIETY OF NEUROSCIENCE, 14 October 2006 (2006-10-14)
JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, 2005, pages 1540
MOL. PSYCHIATR., vol. 6, 2001, pages 217 - 219
MOLECULAR BRAIN RESERCH, vol. 56, no. 1-8, 1998
NEURON, vol. 22, 1999, pages 581 - 591
NEUROPSYCHOPHARMACOLOGY, vol. 28, no. 8, 2003, pages 1400 - 1411
NEUROREPORT, vol. 11, 2000, pages 2017 - 2020
PROG. MED., vol. 5, 1985, pages 2157 - 2161
RINSHO-SEISHIN-YAKURI, vol. 8, no. 12, 2005, pages 2151 - 2164
SYNLETT, vol. 6, 2000, pages 829 - 831
SYNTHETIC COMMUNICATIONS, vol. 11, 1981, pages 513 - 519
TETRAHEDRON LETTERS, vol. 43, 2002, pages 2187
THE JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 123, 2001, pages 7727
TOGOSHICCHOSHO-CHIRYOYAKU TO KANJA ENO SETSUMEI, vol. 54, 2003, pages 287 - 304

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5569857B2 (ja) * 2007-08-10 2014-08-13 アステラス製薬株式会社 二環式アシルグアニジン誘導体
WO2009022633A1 (ja) 2007-08-10 2009-02-19 Astellas Pharma Inc. 二環式アシルグアニジン誘導体
US9469641B2 (en) 2008-03-24 2016-10-18 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
US9260429B2 (en) 2008-03-24 2016-02-16 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
US8853242B2 (en) 2009-08-06 2014-10-07 Astellas Pharma Inc. Nitrogenous-ring acylguanidine derivative
WO2011016504A1 (ja) 2009-08-06 2011-02-10 アステラス製薬株式会社 含窒素環アシルグアニジン誘導体
EP2480079A1 (en) * 2009-09-23 2012-08-01 Medivation Technologies, Inc. Pyrido(3,4-b)indoles and methods of use
EP2480079A4 (en) * 2009-09-23 2015-04-08 Medivation Technologies Inc PYRIDO- (3,4-B-) INDOLE AND USE METHOD THEREFOR
US20120039804A1 (en) * 2010-06-04 2012-02-16 Philippe Diaz Novel Tricyclic Modulators of Cannabinoid Receptors
WO2012105588A1 (ja) * 2011-02-02 2012-08-09 アステラス製薬株式会社 テトラヒドロイソキノリン誘導体
US8962612B2 (en) 2011-02-02 2015-02-24 Astellas Pharma Inc. Tetrahydroisoquinoline derivative
JP5870937B2 (ja) * 2011-02-02 2016-03-01 アステラス製薬株式会社 テトラヒドロイソキノリン誘導体
US11655244B2 (en) 2017-04-11 2023-05-23 Gsno Therapeutics, Inc. Carbazole compounds and methods of use thereof
WO2021193708A1 (ja) * 2020-03-25 2021-09-30 Jnc株式会社 化合物、液晶組成物および液晶表示素子
CN114787130A (zh) * 2020-03-25 2022-07-22 捷恩智株式会社 化合物、液晶组合物及液晶显示元件

Also Published As

Publication number Publication date
JP5287257B2 (ja) 2013-09-11
US20100324017A1 (en) 2010-12-23
EP2119704A1 (en) 2009-11-18
CA2677995A1 (en) 2008-08-14
CN101627013A (zh) 2010-01-13
KR20090114439A (ko) 2009-11-03
EP2119704A4 (en) 2011-06-15
JPWO2008096791A1 (ja) 2010-05-27
MX2009008507A (es) 2009-08-20

Similar Documents

Publication Publication Date Title
WO2008096791A1 (ja) アシルグアニジン誘導体
WO2009022633A1 (ja) 二環式アシルグアニジン誘導体
WO2008034736A3 (en) Oxindole derivatives as anticancer agents
WO2009048101A1 (ja) アミド化合物
WO2005104711A3 (en) Purification of progesterone receptor modulators
WO2007001934A3 (en) Molecular sieve ssz-56 composition of matter and synthesis thereof
WO2010102163A3 (en) Catalysts, processes for making catalysts, processes for making polyolefin compositions and polyolefin compositions
GEP20146033B (en) N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides usage as wnt signaling modulators
AU2011232516A8 (en) Chemical compounds
WO2006136357A3 (de) Kristalline modifikationen des pyraclostrobins
WO2007062190A3 (en) Chemical compounds
DK1710241T3 (da) Intermediatforbindelser til fremstilling af trans-5-chlor-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol
WO2008113559A3 (en) Indolizines and aza-analog derivatives thereof as cns active compounds
WO2009019005A8 (en) Tricyclic bridged cyclopentanedione derivatives as herbicides
WO2010042397A3 (en) Molecular sieve ssz-82 composition of matter and synthesis thereof
WO2010059297A3 (en) Processes using molecular sieve ssz-82
GB0508314D0 (en) Organic compounds
WO2006002185A8 (en) Chemical compounds
MX2012001625A (es) Derivado de acilguanidina de anillo nitrogenado.
EP2148856B8 (en) Catalytic deamination for caprolactam production
MX2010001093A (es) Herbicidas novedosos.
WO2012079085A3 (en) Structure, synthesis, and applications for conjugated polyampholytes
IL208025A0 (en) Spiroindolinone derivatives
WO2006113243A3 (en) Sleeper bunk restraint system for a vehicle
WO2008059339A3 (en) Isoquinoline derivatives as vanilloid receptor modulators

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880004202.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08710858

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008557144

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 4579/CHENP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12526250

Country of ref document: US

Ref document number: 2008710858

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2677995

Country of ref document: CA

Ref document number: MX/A/2009/008507

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097018533

Country of ref document: KR